Therapeutics News and Research

RSS

CRT, EIF create £50M Cancer Research Technology Pioneer Fund

Cancer Research Technology, (CRT) Cancer Research UK's commercial arm, and the European Investment Fund (EIF) have joined together to create a £50M investment fund to bridge the funding gap in the UK between cancer drug discovery and early development.

29 Mar 2012

Positive results from Nile's cenderitide Phase 1 trial on chronic heart failure

Nile Therapeutics, Inc., a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced results from its recently completed Phase 1 clinical trial evaluating the pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of subcutaneous bolus and subcutaneous infusion of cenderitide in patients with chronic heart failure.

29 Mar 2012

Daiichi Sankyo, NGM to discover and develop new treatments for diabetes

Daiichi Sankyo Company, Ltd. and NGM Biopharmaceuticals, Inc. announced today that they have entered into a research collaboration and license agreement to discover and develop novel therapeutics that modulate beta-cell regeneration for the treatment of diabetes.

29 Mar 2012

JDRF, iCo Therapeutics partner for iCo-007 Phase II trial in DME

iCo Therapeutics, a Vancouver-based drug reprofiling company and JDRF, the largest charitable funder of type 1 Diabetes (T1D) research have joined forces to investigate a potential new treatment for one of the most common complications of diabetes, diabetic macular edema.

29 Mar 2012

Ember, Joslin aims to utilize brown fat for treatment of obesity and diabetes

Joslin Diabetes Center and Ember Therapeutics, Inc. today announced an agreement aimed at utilizing "brown fat," a type of fat that helps increase energy expenditure within the body, as a novel technique for managing obesity and diabetes. Joslin's Chief Academic Officer, Dr. Ronald Kahn and other Joslin faculty, Drs. Yu-Hua Tseng and Aaron Cypess, have performed pioneering work in this field over the past several years, and were the first to show that a natural protein called BMP7 can help modulate the levels of brown fat.

29 Mar 2012

Regulatory agencies approve plans for e-Therapeutics' ETS2101 phase I trials in cancer

e-Therapeutics plc announces that regulatory agencies in the UK and the US have approved plans for phase I trials of the Company's anti-cancer drug ETS2101 and that enrolment of patients into trials in these two countries will begin shortly.

29 Mar 2012

Gene therapy improves chylomicron metabolism in LPLD patients

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today data demonstrating that one-time administration of the gene therapy Glybera (alipogene tiparvovec) is able to markedly improve chylomicron (fat particles in the blood) metabolism following consumption of a low fat meal.

29 Mar 2012

Althea provides Allena exclusive worldwide rights to broad hyperoxaluria portfolio

Allena Pharmaceuticals, Inc., and Althea Technologies today announced a licensing agreement under which Allena has obtained the exclusive worldwide rights to Althea's broad hyperoxaluria portfolio including product patents, regulatory information and development data related to oxalate degrading enzymes.

29 Mar 2012

Galectin closes underwritten public offering of 1,333,361 units

Galectin Therapeutics Inc. today announced it has closed its underwritten public offering of 1,333,361 units (including 173,916 units that were offered and sold by Galectin pursuant to the exercise in-full of the underwriter's over-allotment option) at a price to the public of $9.00 per unit, with each unit consisting of two common voting shares, par value $0.001 per share and one warrant to purchase one share of Common Stock.

29 Mar 2012

Researchers profile genetic changes in cancer with drug sensitivity

In the largest study of its kind, researchers have profiled genetic changes in cancer with drug sensitivity in order to develop a personalised approach to cancer treatments. The study is published in Nature on Thursday 29 March 2012.

29 Mar 2012

Pernix fourth quarter net revenues increase 74% to $21.4 million

Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, today announced financial results for the quarter and year ended December 31, 2011.

29 Mar 2012

ACCR designates Georgetown student as early-career scientist

David A. Solomon, who will graduate from Georgetown University School of Medicine this year with M.D. and Ph.D. degrees, has been designated one of four outstanding early-career scientists by the American Association for Cancer Research (AACR) -- a highly prestigious honor. Solomon will present his work at a special symposium, Future Leaders in Basic Cancer Research, on April 2nd at the AACR Annual Meeting 2012 in Chicago.

28 Mar 2012

Magnetic iron oxide nanoparticle-induced hyperthermia can kill cancer cells

Using nanoparticles and alternating magnetic fields, University of Georgia scientists have found that head and neck cancerous tumor cells in mice can be killed in half an hour without harming healthy cells.

28 Mar 2012

Data supports links between AD and diabetes: New study

Alzheimer's disease is the sixth leading cause of death in the United States and the only cause of death among the top 10 in America without a way to prevent, cure or even slow its progression, according to the Alzheimer's Association. Today, 5.4 million Americans are living with the disease, and another American develops it every 69 seconds.

28 Mar 2012

New pre-clinical data on Rexahn's RX-3117 study to be presented at AACR meeting

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it will present new pre-clinical data on its oncology compound RX-3117 during a poster session at the American Association for Cancer Research (AACR) 103rd Annual Meeting being held in Chicago, Illinois, March 31 - April 4, 2012, at the McCormick Place Convention Center.

28 Mar 2012

Therapy Finder - Colorectal Cancer app now available for patients

No one wants to hear the words, "you have colon cancer." For patients diagnosed with an advanced form of the disease, these words can be particularly devastating. The five-year survival rate can be a little as 6 percent. The top-of-mind question becomes, "Which treatment or clinical trial will work for me?"

28 Mar 2012

UT Southwestern researcher wins prestigious award from International Atherosclerosis Society

Dr. Helen Hobbs, a preeminent researcher on the genetics of cholesterol metabolism at UT Southwestern Medical Center, has won a prestigious award from the International Atherosclerosis Society.

28 Mar 2012

Researchers develop gut-on-a-chip microdevice

Researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University have created a gut-on-a-chip microdevice lined by living human cells that mimics the structure, physiology, and mechanics of the human intestine-even supporting the growth of living microbes within its luminal space.

28 Mar 2012

Top-line results from two Targacept TC-6987 Phase 2 studies on asthma, type 2 diabetes

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced top-line results from two separate exploratory Phase 2 studies of its product candidate TC-6987 conducted in the United States, one in asthma and one in type 2 diabetes.

28 Mar 2012

Study reveals how HSV-1 virus overcomes intrinsic host defenses

New biological research reveals how an invading virus hijacks a cell's workings by imitating a signaling marker to defeat the body's defenses. By manipulating cell signals, the virus destroys a defensive protein designed to inhibit it. This finding, from studies in human cell cultures, may represent a broader targeting strategy used by other viruses, and may lay the scientific groundwork for developing more effective treatments for infectious diseases.

27 Mar 2012